Research map: Efficacy and safety of finerenone with or without combination therapy in patients with non-diabetic chronic kidney disease: a real-world observational study

Back to the article

Papers in this map

  1. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease · Paul E. Stevens · 2024 · 8239 citations · Cited by this paper
  2. Improving eGFR estimation in diabetic populations: insights from real-world data · 2026 · Related
  3. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes · George L. Bakris · 2020 · 2886 citations · Cited by this paper
  4. An 84-year-old man presenting with febrile cytopenia and acute glomerular disease. Lessons for the Clinical Nephrologist · 2026 · Related
  5. Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes · Bertram Pitt · 2021 · 1742 citations · Cited by this paper
  6. Decoding hemodialysis patients' symptoms: navigating the complexity · 2026 · Related
  7. Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses From the FIGARO-DKD Trial · Gerasimos Filippatos · 2021 · 283 citations · Cited by this paper
  8. Prenatal exposure to environmental toxicants and their association with alterations in kidney development · 2026 · Related
  9. Mineralocorticoid receptor antagonists in diabetic kidney disease — mechanistic and therapeutic effects · Jonatan Barrera‐Chimal · 2021 · 252 citations · Cited by this paper
  10. Hidden glyoxylic acid in hair straightening products: a forensic lesson for the nephrologist · 2026 · Related
  11. The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics · David Collins. Wheeler · 2020 · 198 citations · Cited by this paper
  12. The association between plasma aldosterone level, transtubular potassium gradient, or their ratios and causes of hyperkalemia in the outpatient setting · 2026 · Related
  13. The major global burden of chronic kidney disease · Michel Y. Jadoul · 2024 · 171 citations · Cited by this paper
  14. Association of pre-donation microalbuminuria with accelerated kidney function impairment in living kidney donors: a retrospective cohort study · 2026 · Related
  15. Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice · Megumi Oshima · 2020 · 166 citations · Cited by this paper
  16. Pediatric hematuria as a gateway to family genetic investigation in type IV collagen nephropathies: experience from a regional cohort · 2026 · Related
  17. Design of the COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint study (CONFIDENCE) · Jennifer B. Green · 2022 · 165 citations · Cited by this paper
  18. Telitacicept treatment for active antibody-mediated rejection after kidney transplantation: a case series · 2026 · Related
  19. Correlates and Consequences of an Acute Change in eGFR in Response to the SGLT2 Inhibitor Dapagliflozin in Patients with CKD · Niels Jongs · 2022 · 92 citations · Cited by this paper
  20. Indirect effect of the COVID-19 pandemic on mortality, complications, and healthcare utilization among people with Chronic Kidney Disease in Hong Kong: an interrupted time series analysis · 2026 · Related
  21. SGLT2i for evidence-based cardiorenal protection in diabetic and non-diabetic chronic kidney disease: a comprehensive review by EURECA-m and ERBP working groups of ERA · Patrick Barry Mark · 2023 · 66 citations · Cited by this paper
  22. Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory post hoc analyses from FIDELIO-DKD compared to reported CREDENCE results · Rajiv Agarwal · 2021 · 64 citations · Cited by this paper
  23. Influence of SGLT2i and RAASi and Their Combination on Risk of Hyperkalemia in DKD · Xiaoling Luo · 2023 · 44 citations · Cited by this paper
  24. Rationale, Design, and Baseline Characteristics of ARTS-DN: A Randomized Study to Assess the Safety and Efficacy of Finerenone in Patients with Type 2 Diabetes Mellitus and a Clinical Diagnosis of Diabetic Nephropathy · Luis Miguel Ruilope · 2014 · 41 citations · Cited by this paper
  25. Efficacy and safety of finerenone in patients with an acute change in estimated glomerular filtration rate in the prespecified FIDELITY pool analysis · Sankar Dass Navaneethan · 2025 · 20 citations · Cited by this paper
  26. Observation of the therapeutic effect of finerenone, a novel non-steroidal mineralocorticoid receptor antagonist, in patients with non-diabetic CKD · Fang Li · 2025 · 7 citations · Cited by this paper
  27. Early Efficacy and Safety of Finerenone on Type 2 Diabetes‐Related Chronic Kidney Disease: A Real‐World Observational Study in China · Liyu Lin · 2025 · 6 citations · Cited by this paper

Source: OpenAlex (CC0)